Rebiotix completes enrollment for phase 3 trial of C. diff microbiota therapy

Investigators have completed enrollment in a phase 3 trial set to investigate RBX2660, a therapy that uses the gut microbiota to treat Clostridioides difficile infection, according to a press release issued by Rebiotix, the manufacturer.The company said this is the first microbiota-based formulation to reach phase 3 in the United States and Canada.“Microbiota-based therapies have shown tremendous potential as an innovative, non-antibiotic therapy, starting with C. diff,” Rebiotix founder and CEO Lee Jones said in the press release. The completion of enrollment of this trial is aRead More